- Home
- LPTX vs GLU Comparison
LPTX vs GLU Comparison
Compare LPTX & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- GLU
- Stock Information
- Founded
- LPTX 2011
- GLU 2004
- Country
- LPTX United States
- GLU United States
- Employees
- LPTX N/A
- GLU N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- GLU Finance/Investors Services
- Sector
- LPTX Health Care
- GLU Finance
- Exchange
- LPTX Nasdaq
- GLU Nasdaq
- Market Cap
- LPTX 99.5M
- GLU 99.0M
- IPO Year
- LPTX N/A
- GLU N/A
- Fundamental
- Price
- LPTX $3.11
- GLU $16.03
- Analyst Decision
- LPTX Strong Buy
- GLU
- Analyst Count
- LPTX 3
- GLU 0
- Target Price
- LPTX $7.50
- GLU N/A
- AVG Volume (30 Days)
- LPTX 437.3K
- GLU 12.4K
- Earning Date
- LPTX 11-13-2024
- GLU 01-01-0001
- Dividend Yield
- LPTX N/A
- GLU 8.60%
- EPS Growth
- LPTX N/A
- GLU N/A
- EPS
- LPTX N/A
- GLU 0.62
- Revenue
- LPTX N/A
- GLU N/A
- Revenue This Year
- LPTX N/A
- GLU N/A
- Revenue Next Year
- LPTX N/A
- GLU N/A
- P/E Ratio
- LPTX N/A
- GLU $22.50
- Revenue Growth
- LPTX N/A
- GLU N/A
- 52 Week Low
- LPTX $1.68
- GLU $11.61
- 52 Week High
- LPTX $5.00
- GLU $15.40
- Technical
- Relative Strength Index (RSI)
- LPTX 51.79
- GLU 45.53
- Support Level
- LPTX $2.87
- GLU $15.93
- Resistance Level
- LPTX $3.12
- GLU $16.48
- Average True Range (ATR)
- LPTX 0.28
- GLU 0.33
- MACD
- LPTX 0.02
- GLU -0.04
- Stochastic Oscillator
- LPTX 49.42
- GLU 29.73
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.